Registry of Lobbyists

Monthly Communication Report

369785-627837

Corporation: Organon Canada Inc.
Associated registration: 949479-369785-9
Communication date: 2024-11-18
Posted date: 2024-12-17

Designated Public Office Holders who participated in the communication: Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health
Health Canada (HC)
 
List of Details
Subject matter Detail
Economic Development, Health Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
Health Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
Health To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
Economic Development, Health To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
 
Responsible Officer who filed this communication report: Michael Casia
 
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication.

The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
 

Date Modified: